Bio-Technology General, Genentech metabolic news

The U.S. Court of Appeals for the Federal Circuit affirmed GNE's preliminary injunction against U.S. sales of Bio-Tropin, BTGC's human growth hormone. The court found that GNE had established a "reasonable likelihood of success on the merits of its patent infringement claim." GNE alleges that BTGC infringes GNE's U.S. patents that relate to the manufacture of hGH. The case now returns to the U.S. District Court in New York for possible trial. ...